Literature DB >> 10626670

Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations.

G Hermans1, R Medaer, J Raus, P Stinissen.   

Abstract

Pathogenic autoreactive T cells can be targeted by T cell vaccination (TCV), a procedure in which patients are immunized with autologous attenuated pathogenic T cells. We reported previously that TCV with myelin basic protein (MBP) reactive T cell clones in multiple sclerosis (MS) patients induced T cell immune responses, resulting in a clonal depletion of MBP reactive T cells in all patients. Five years after TCV, MBP reactive T cells were observed in five out of nine MS patients. These clones had a different clonal origin from those isolated before vaccination. We have studied the cytokine profile, cytotoxicity and epitope specificity of these reappearing clones. Our data indicate that the clones express similar effector functions as those isolated before TCV, suggesting that they also could play a pathogenic role in the disease. We demonstrated that these clones can be depleted by an additional sequence of immunizations. These findings may be relevant to other T cell targeted immunotherapies for MS and other autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10626670     DOI: 10.1016/s0165-5728(99)00157-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Immunologic therapy for secondary and primary progressive multiple sclerosis.

Authors:  L W Myers
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 4.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 5.  Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.

Authors:  Arthur A Vandenbark; Rivka Abulafia-Lapid
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

6.  T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Authors:  A Van der Aa; N Hellings; R Medaer; G Gelin; Y Palmers; J Raus; P Stinissen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

7.  T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Authors:  Dimitrios Karussis; Hagai Shor; Julia Yachnin; Naama Lanxner; Merav Amiel; Keren Baruch; Yael Keren-Zur; Ofra Haviv; Massimo Filippi; Panayiota Petrou; Shalom Hajag; Urania Vourka-Karussis; Adi Vaknin-Dembinsky; Salim Khoury; Oded Abramsky; Henri Atlan; Irun R Cohen; Rivka Abulafia-Lapid
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

Review 8.  Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients.

Authors:  Andreas Lutterotti; Helen Hayward-Koennecke; Mireia Sospedra; Roland Martin
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

Review 9.  Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Authors:  Rongzeng Liu; Shushu Du; Lili Zhao; Sahil Jain; Kritika Sahay; Albert Rizvanov; Vera Lezhnyova; Timur Khaibullin; Ekaterina Martynova; Svetlana Khaiboullina; Manoj Baranwal
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

10.  Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis.

Authors:  Barbara Willekens; Nathalie Cools
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.